These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 30154547

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.
    Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H.
    Oncotarget; 2014 Oct 30; 5(20):9650-63. PubMed ID: 25333260
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS, Provan PJ, Kim E, Pathmanathan N, Graham D, Clarke CL, Balleine RL.
    Clin Exp Metastasis; 2018 Feb 30; 35(1-2):3-13. PubMed ID: 29214365
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. HER2 as a prognostic factor in breast cancer.
    Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A.
    Oncology; 2001 Feb 30; 61 Suppl 2():67-72. PubMed ID: 11694790
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Identification of serum exosomal miR-148a as a novel prognostic biomarker for breast cancer.
    Li D, Wang J, Ma LJ, Yang HB, Jing JF, Jia MM, Zhang XJ, Guo F, Gao JN.
    Eur Rev Med Pharmacol Sci; 2020 Jul 30; 24(13):7303-7309. PubMed ID: 32706068
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation.
    Li S, Meng H, Zhou F, Zhai L, Zhang L, Gu F, Fan Y, Lang R, Fu L, Gu L, Qi L.
    Pathol Res Pract; 2013 Mar 30; 209(3):179-83. PubMed ID: 23399321
    [Abstract] [Full Text] [Related]

  • 12. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC.
    Petrovic N, Sami A, Martinovic J, Zaric M, Nakashidze I, Lukic S, Jovanovic-Cupic S.
    Pathol Res Pract; 2017 Oct 30; 213(10):1264-1270. PubMed ID: 28935174
    [Abstract] [Full Text] [Related]

  • 13. Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
    Li M, Zhou Y, Xia T, Zhou X, Huang Z, Zhang H, Zhu W, Ding Q, Wang S.
    Breast Cancer Res Treat; 2018 Jul 30; 170(2):257-270. PubMed ID: 29557526
    [Abstract] [Full Text] [Related]

  • 14. Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients.
    Niedźwiecki S, Piekarski J, Szymańska B, Pawłowska Z, Jeziorski A.
    Ginekol Pol; 2018 Jul 30; 89(8):415-420. PubMed ID: 30215459
    [Abstract] [Full Text] [Related]

  • 15. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.
    Hannafon BN, Sebastiani P, de las Morenas A, Lu J, Rosenberg CL.
    Breast Cancer Res; 2011 Mar 04; 13(2):R24. PubMed ID: 21375733
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E, Isayeva T, Wei S, Almeida JS, Harada S.
    Cancer Control; 2017 Jan 04; 24(1):102-110. PubMed ID: 28178722
    [Abstract] [Full Text] [Related]

  • 19. Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer.
    Müller V, Oliveira-Ferrer L, Steinbach B, Pantel K, Schwarzenbach H.
    Mol Oncol; 2019 May 04; 13(5):1137-1149. PubMed ID: 30803129
    [Abstract] [Full Text] [Related]

  • 20. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM, Sreedhara M, Chen YH, Bellon JR, Punglia RS, Wong JS, Harris JR, Brock JE.
    Int J Radiat Oncol Biol Phys; 2012 Mar 15; 82(4):e581-6. PubMed ID: 22208975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.